Detalhe da pesquisa
1.
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Cancer Sci
; 115(4): 1296-1305, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402853
2.
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Br J Cancer
; 130(10): 1679-1686, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575731
3.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469185
4.
Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Invest New Drugs
; 38(5): 1507-1519, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32221754
5.
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
Jpn J Clin Oncol
; 50(8): 859-866, 2020 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32328660
6.
Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.
Drug Metab Dispos
; 45(2): 174-182, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27934635
7.
Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.
Br J Clin Pharmacol
; 82(6): 1498-1508, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27483391
8.
Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence.
JCO Precis Oncol
; 8: e2300328, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354329
9.
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Mol Cancer Ther
; 22(7): 833-843, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999986
10.
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.
Clin Cancer Res
; 29(10): 1879-1886, 2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36971777
11.
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.
Cell Rep Med
; 4(11): 101280, 2023 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37944528
12.
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 9(9): 1260-1266, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37270698
13.
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.
Biopharm Drug Dispos
; 33(9): 550-9, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23097240
14.
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Cancer Chemother Pharmacol
; 90(1): 53-69, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35771259
15.
Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study.
Clin Transl Sci
; 15(8): 1990-1998, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661422
16.
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
CPT Pharmacometrics Syst Pharmacol
; 10(5): 428-440, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33818908
17.
Real-world insights into patients with advanced NSCLC and MET alterations.
Lung Cancer
; 159: 96-106, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34320421
18.
Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Clin Transl Sci
; 13(2): 325-336, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31654487
19.
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Lancet Respir Med
; 8(11): 1132-1143, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32479794
20.
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 26(6): 1237-1246, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31822497